The congress of the SPIN was a great opportunity to learn about innovations in the field of inflammatory dermatoses, in particular regarding psoriasis. Insights into the pathomechanisms and the mode of action of treatments have developed substantially during the last three years. Effective and safe control of psoriasis and eczema by targeted treatments has become reality.
Whereas topical therapies are the main stay in the first phases of psoriasis, systemic therapies become much more upfront, and dermatologists realise that psoriasis is, to a large extent, a systemic disease. It is the implementation of new biologics (three anti IL-17 molecules and three anti IL-23 molecules) together with the development of small molecules that revolutionises the treatment of p...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Small molecules, apremilast, and TYK2 Next Article
Treatment goals in psoriasis »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.